Dr. Ravi Salgia from University of Chicago discusses his perspective on side effects of targeted therapies as compared with standard chemotherapy for patients with lung cancer.
[powerpress]
Dr. Oxnard from Dana Farber Cancer Institute provides his insight on which patients with advanced non-small cell lung cancer he pursues molecular testing for, and which molecular markers are the highest priority.
[powerpress]
Dr. David Spigel from Sarah Cannon Cancer Center offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.
[powerpress]
The question of how best to manage "acquired resistance" to a targeted therapy like an EGFR or ALK inhibitor in someone who has had a great response for a long time can be complicated and really doesn't have a best answer. However, other doctors and many patients here and in the brick and mortar world ask me about how I approach it, and I've got some real opinions about it. I'll qualify my further comments by saying that my own views have evolved over the years as we've gained more information as we get more clinical data and practical experience.
Introduction
Thank you to member Craig for asking some excellent questions in response to my Highlights of 2011 webinar. Thank you also to Dr. West, who emailed me to comment more on the idea of radiation for cells with acquired resistance.
We’ve spoken at length about EGFR and related mutations such as EML4/ALK and ROS1 on GRACE. For those who are not familiar with these subjects, I will refer you to my webinar for a summary on the most recent data on EGFR, EML4/ALK and ROS1:
Following the terrific presentations by Drs. Ben Solomon and Ross Camidge on the science and clinical experience with the novel ALK inhibitor XALKORI (crizotinib), we had a question and answer session, which is now available as a podcast. Here's the audio podcast and transcript for it (not really a video component for this one).
[powerpress]
Continuing with Dr. Ross Camidge as our focus (see yesterday's post for a brief update from him on the afatinib/cetuximab trial), today let's turn to the recent webinar program he and Dr. Ben Solomon did with us on the subject of ALK Inhibition: From Biology to FDA-Approved Therapy for Advanced NSCLC". After Dr.
A year ago, almost to the day, we presented an excellent podcast by Dr. Ross Camidge at the University of Colorado, describing the very new and promising work on the Pfizer investigational agent crizotinib for the subset (4-5% of patients with NSCLC) who have an ALK rearrangement.
The following is the edited transcript and figures from a webinar presentation made by Dr. Heather Wakelee, medical oncologist and Associate Professor at Stanford Cancer Center, on Never-Smokers and Gender Differences in Lung Cancer.
Copyright © 2021 Global Resource for Advancing Cancer Education
Site by Freelock